Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  He, Jiabei ^a   Hu, Ying ^a   Hu, Mingming ^a   Li, Baolan ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD274 PROTEIN, HUMAN; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; TUMOR MARKER;

CARCINOMA, NON-SMALL-CELL LUNG; COMBINATION DRUG THERAPY; HUMAN; IMMUNOLOGY; LUNG NEOPLASMS; METABOLISM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD274; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CARCINOMA, NON-SMALL-CELL LUNG; DRUG THERAPY, COMBINATION; HUMANS; LUNG NEOPLASMS; PROGRAMMED CELL DEATH 1 RECEPTOR; TUMOR MICROENVIRONMENT;

EID: 84939456588     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep13110     Document Type: Article

References (70)

1. Hao, J. & Chen, W. Q. 2012 Chinese cancer registry annual report. 28-30 (Beijing Military medical Science Press, 2012).
2. Zheng, Y. W., Li, R. M., Zhang, X. W. & Ren, X. B. Current adoptive immunotherapy in non-small cell lung cancer and potential influence of therapy outcome. Cancer Invest. 31, 197-205 (2013).
3. Sjöblom, T. et al. The consensus coding sequences of human breast and colorectal cancers. J. Science. 314, 268-274 (2006).
4. Mosmann, T. R. & Sad, S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today. 17, 138-46 (1996).
5. Zou, W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. J. Nat Rev Cancer. 5, 263-274 (2005).
6. Fife, B. T. & Bluestone, J. A. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. J. Immunological reviews. 224, 166-182 (2008).
7. Ceeraz, S., Nowak, E. C. & Noelle, R. J. B7 family checkpoint regulators in immune regulation and disease. J. Trends Immunol. 34, 556-563 (2013).
8. Riley, J. L. PD-1 signaling in primary T cells. J. Immunological reviews. 229, 114-125 (2009).
9. Keir, M. E., Butte, M. J., Freeman, G. J. & Sharpe, A. H. PD-1 and its ligands in tolerance and immunity. J. Annu Rev Immunol. 26, 677-704 (2008).
10. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. J Exp Med. 206, 3015-3029 (2009).
11. Velcheti, V. et al. Programmed death ligand-1 expression in non-small cell lung cancer. J. Laboratory Investigation. 94, 107-116 (2013).
12. Boland, J. M. et al. Tumor B7-H1 and B7-H3 expression in squamous cell carcinoma of the lung. J. Clin Lung Cancer. 14, 157-163 (2013).
13. Spranger, S. et al. Up-regulation of PD-L1, IDO, and Tregs in the melanoma tumor microenvironment is driven by CD8+ T cells. J. Sci Transl Med. 5 (200): 200ra116 (2013).
14. Thompson, R. H. et al. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma. J. Cancer. 104, 2084-2091 (2005).
15. Bernstein, M. B. et al. Radiation-Induced Modulation of Costimulatory and Coinhibitory T-Cell Signaling Molecules on Human Prostate Carcinoma Cells Promotes Productive Antitumor Immune Interactions. J. Cancer Biother Radio. 29, 153-161 (2014).
16. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. J. Nature Medicine. 8, 793-800 (2002).
17. Taube, J. M. et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. J. Sci Transl Med. 4, 127ra37 (2012).
18. Sznol, M. & Chen, L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. J. Clin Cancer Res. 19, 1021-1034 (2013).
19. Kondo, A. et al. Interferon-γ and tumor necrosis factor-α induce an immunoinhibitory molecule, B7-H1, via nuclear factor-κ B activation in blasts in myelodysplastic syndromes. J. Blood. 116, 1124-1131 (2010).
20. Crane, C. A. et al. PI (3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer. J. Oncogene. 28, 306-312 (2008).
21. Parsa, A. T. et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. J. Nature Medicine. 13, 84-88 (2006).
22. Gong, A. Y. et al. MicroRNA-513 regulates B7-H1 translation and is involved in IFN-γ-induced B7-H1 expression in cholangiocytes. J. J Immunol. 182, 1325-1333 (2009).
23. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. J. Immunity. 27, 111-122 (2007).
24. Hiraoka, N. Tumor-infiltrating lymphocytes and hepatocellular carcinoma: molecular biology. Int J Clin Oncol. 15, 544-551 (2010).
25. Pardoll, D. M. The blockade of immune checkpoints in cancer immuno-therapy. Nat Rev Cancer. 12, 252-264 (2012).
26. Ramsay, A. G. Immune checkpoint blockade immunotherapy to activate anti-tumour T-cell immunity. Br J Haematol. 162, 313-325 (2013).
27. Li, J. PD-1/SHP-2 Inhibits Tc1/Th1 Phenotypic Responses and the Activation of T Cells in the Tumor Microenvironment. Cancer Res. 75(3), 508-518 (2015).
28. Curiel, T. J. et al. Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunity. J. Nature Medicine. 9, 562-567 (2003).
29. Parkin, D. M. The global health burden of infection-associated cancers in the year 2002. J. Int J Clin Oncol. 118, 3030-3044 (2006).
30. Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infectionv. J. Nature. 439, 682-687 (2005).
31. Duraiswamy, J., Freeman, G. J. & Coukos, G. Therapeutic PD-1 pathway blockade augments with other modalities of immunotherapy T-cell function to prevent immune decline in ovarian cancer. J. Cancer Research. 73, 6900-6912 (2013).
32. Francisco, L. M. et al. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. J Exp Med. 206, 3015-3029 (2009).
33. Sheppard, K. A. et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3 signalosome and downstream signaling to PKCθ . J. FEBS Letters. 574, 37-41 (2004).
34. Patsoukis, N., Sari, D. & Boussiotis, V. A. PD-1 inhibits T cell proliferation by upregulating p27 and p15 and suppressing Cdc25A. J. Cell Cycle. 11, 4305-4309 (2012).
35. Charlton, J. J. et al. Programmed death-1 shapes memory phenotype CD8 T cell subsets in a cell-intrinsic manner. J. J Immunol. 190, 6104-6114 (2013).
36. Paterson, A. M. et al. The programmed death-1 ligand 1: B7-1 pathway restrains diabetogenic effector T cells in vivo. J. J Immunol. 187, 1097-1105 (2011).
37. Brahmer, J. R. Harnessing the immune system for the treatment of non-small-cell lung cancer. J. J Clin Oncol. 31, 1021-1028 (2013).
38. Mu, C. Y., Huang, J. A., Chen, Y., Chen, C. & Zhang, X. G. High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation. J. Med Oncol. 28, 682-688 (2011).
39. Sun J.-M. et al. Abstract 8066. Presented at:2014 Annual Meeting of ASCO; May 30-June 30; Chicago, IL, USA
40. Gao, Q. et al. Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. J. Clin Cancer Res. 15, 971-979 (2009).
41. Yang, C. Y., Lin, M. W., Chang, Y. L., Wu, C. T. & Yang, P. C. et al. Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes. J. Eur J Cancer. 50, 1361-1369 (2014).
42. Sasaki, H., Tatemaysu, T. & Okuda, K. et al. PD-1 gene promoter polymorphisms correlate with a poor prognosis in non-small cell lung cancer. J. J Cancer Res Clin. 2 (6), 1035-1042 (2014).
43. Azuma, K. et al. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected non-small cell lung cancer. J. Ann Oncol, mdu242 (2014).
44. Garon, E. B. et al. Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer. J. N Engl J Med. 372, 2018-2028 (2015).
45. Topalian, S. L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. J. N Engl J Med. 366, 2443-2454 (2012).
46. Antonia, S. J. et al. Association of tumor PD-L1 expression and immune biomarkers with clinical activity in patients with nonsmall cell lung cancer (NSCLC) treated with nivolumab (Anti-PD-1; BMS-936558; ONO-4538). J Thorac Oncol. 8, S907-S908 (2013).
47. D'Incecco, A. et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. J. Br J Cancer. 112, 95-102 (2015).
48. Zhang, Y., Huang, S., Gong, D., Qin, Y. & Shen, Q. Programmed death-1 upregulation is correlated with dysfunction of tumorinfiltrating CD8± T lymphocytes in human non-small cell lung cancer. J. Cellular & Molecular Immunology. 7, 389-395 (2010).
49. Brahmer, J. R. et al. Nivolumab (anti-PD-1; BMS-936558; ONO-4538) in patients with non-small cell lung cancer (NSCLC): overall survival and long-term safety in a phase 1 trial. J. J Thorac Oncol. 8, S365-S366 (2013).
50. Garon, E. et al. Preliminary clinical safety and activity of MK-3475 monotherapy for the treatment of previously treated patients with non-small cell lung cancer (NSCLC). J. J Thorac Oncol. 8, S364-S365 (2013).
51. Philips, G. K. & Atkins, M. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies. J. Int Immunol. 27, 39-46 (2014).
52. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. J. N Engl J Med. 366, 2455-2465 (2012).
53. Herbst, R. S. et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J. J Clin Oncol. 31(No 15suppl):3000 (2013).
54. Spigel, D. R. et al. Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). J. J Clin Oncol. 31, 3622 (2013).
55. Powderly, J. D. et al. Biomarkers and associations with the clinical activity of PD-L1 blockade in a MPDL3280A study. J. J Clin Oncol. 31, 3001 (2013).
56. Khleif, S. et al. MEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase I study in patients with advanced solid tumors. J. Eur J Cancer. 49, S161 (2013).
57. Lutzky, J., Antonia, S. J. & Blake-Haskins, A. et al. A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. J. J Clin Oncol. 32, 3001 (2014).
58. Brahmer, J. R., Rizvi, N. A. & Lutzky. J. et al. Clinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLC. J Clin Oncol. 32, 8021 (2014).
59. Mkrtichyan, M. et al. B7-DC-Ig enhances vaccine effect by a novel mechanism dependent on PD-1 expression level on T cell subsets. J. The Journal of Immunology. 189, 2338-2347 (2012).
60. Smothers, F. J. AMP-224, a fusion protein that targets PD-1. J. Ann Oncol. 24, i7 (2013).
61. Deng, L. F. et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. J Clin Invest. 124, 687-695 (2014).
62. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. J. Nature Reviews Cancer. 12, 237-251 (2012).
63. Bald, T. et al. Immune Cell-Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation. J. Cancer Discovery. 4, 674-687 (2014).
64. Antonia, S. J., Gettinger, S. N. & Chow, L. Q. M. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) and ipilimumab in first-line NSCLC: interim phase I results. J. J Clin Oncol. 32, 5s (2014).
65. Antonia, S. J. et al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC). J. International Journal of Radiation Oncology Biology Physics. 90, S2 (2014).
66. Duraiswamy, J., Kaluza, K. M., Freeman, G. J. & Coukos, G. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. J. Cancer Research. 73, 3591-3603 (2013).
67. Zeng, J. Anti-PD-1 Blockade and Stereotactic Radiation Produce Long-Term Survival in Mice With Intracranial Gliomas. Int J Radiat Oncol Biol Phys 86 (2), 343-349 (2013).
68. Sean, S. P., Michael, G., Keith, M. F. & Kenneth, R. O. PD-1 Restrains Radiotherapy-Induced Abscopal Effect. Cancer Immunology Research Feb 19 (2015).
69. Simon, J. D. et al. Acquired Resistance to Fractionated Radiotherapy Can Be Overcome by Concurrent PD-L1 Blockade. Cancer Research Oct 74, 5458 (2014).
70. Choueiri, T. K. et al. PD-L1 expression in nonclear-cell renal cell carcinoma. J. Ann Oncol. 25, 2178-2184 (2014).